PI3-kinase and TOR: PIKTORing cell growth

Seminars in Cell and Developmental Biology

Volumn 15, Issue 2, 2004, Pages 147-159

  Richardson, Celeste J ^a   Schalm, Stefanie S ^a   Blenis, John ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

PI3K; Rapamycin; TOR; TSC; Wortmannin

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEASOME INHIBITOR; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE; WORTMANNIN;

CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; DROSOPHILA; DRUG EFFECT; EUKARYOTIC CELL; NONHUMAN; REVIEW; TRANSLATION REGULATION; TUMOR;

EUKARYOTA;

EID: 1342279422     PISSN: 10849521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcdb.2003.12.023     Document Type: Article

References (146)

1. Rameh L.E., Cantley L.C. The role of phosphoinositide 3-kinase lipid products in cell function. J. Biol. Chem. 274(13):1999;8347-8350.
2. Heitman J., Movva N.R., Hall M.N. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science. 253(5022):1991;905-909.
3. Cafferkey R., Young P.R., McLaughlin M.M., Bergsma D.J., Koltin Y., Sathe G.M.et al. Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity. Mol. Cell Biol. 13(10):1993;6012-6023.
4. Kunz J., Henriquez R., Schneider U., Deuter-Reinhard M., Movva N.R., Hall M.N. Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression. Cell. 73(3):1993;585-596.
5. Brown E.J., Albers M.W., Shin T.B., Ichikawa K., Keith C.T., Lane W.S.et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 369(6483):1994;756-758.
6. Chiu M.I., Katz H., Berlin V. RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proc. Natl. Acad. Sci. USA. 91(26):1994;12574-12578.
7. Sabatini D.M., Erdjument-Bromage H., Lui M., Tempst P., Snyder S.H. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell. 78(1):1994;35-43.
8. Sabers C.J., Martin M.M., Brunn G.J., Williams J.M., Dumont F.J., Wiederrecht G.et al. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J. Biol. Chem. 270:1995;815-822.
9. Rohde J., Heitman J., Cardenas M.E. The TOR kinases link nutrient sensing to cell growth. J. Biol. Chem. 276(13):2001;9583-9586.
10. Schmelzle T., Hall M.N. TOR, a central controller of cell growth. Cell. 103(2):2000;253-262.
11. Barbet N.C., Schneider U., Helliwell S.B., Stansfield I., Tuite M.F., Hall M.N. TOR controls translation initiation and early G1 progression in yeast. Mol. Biol. Cell. 7(1):1996;25-42.
12. Oldham S., Montagne J., Radimerski T., Thomas G., Hafen B. Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycin. Genes Dev. 14(21):2000;2689-2694.
13. Zhang H., Stallock J.P., Ng J.C., Reinhard C., Neufeld T.P. Regulation of cellular growth by the Drosophila target of rapamycin dTOR. Genes Dcv. 14(21):2000;2712-2724.
14. Hara K., Yonezawa K., Weng Q.P., Kozlowski M.T., Belham C., Avruch J. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J. Biol. Chem. 273(23):1998;14484-14494.
15. Dennis P.B., Jaeschke A., Saitoh M., Fowler B., Kozma S.C., Thomas G. Mammalian TOR: a homeostatic ATP sensor. Science. 294(5544):2001;1102-1105.
16. Kimura N., Tokunaga C., Dalal S., Richardson C., Yoshino K., Hara K.et al. A possible linkage between AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway. Genes Cells. 8(1):2003;65-79.
17. Hardie D.G., Hawley S.A. AMP-activated protein kinase: the energy charge hypothesis revisited. Bioessays. 23(12):2001;1112-1119.
18. Inoki K., Zhu T., Guan K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 115:2003;577-590.
19. Fang Y., Vilella-Bach M., Bachmann R., Flanigan A., Chen J. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science. 294(5548):2001;1942-1945.
20. Gingras A.C., Raught B., Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 15(7):2001;807-826.
21. Martin K.A., Blenis J. Coordinate regulation of translation by the PI 3-kinase and mTOR pathways. Adv. Cancer Res. 86:2002;1-39.
22. Montague J., Radimerski T., Thomas G. Insulin signaling: lessons from the Drosophila tuberous sclerosis complex, a tumor suppressor. Sci. STKE. 2001(105):2001;PE36.
23. van Slegtenhorst M., Nellist M., Nagelkerken B., Cheadle J., Snell R., van den Ouweland A.et al. Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hum. Mol. Genet. 7(6):1998;1053-1057.
24. Goncharova E.A., Goncharov D.A., Eszterhas A., Hunter D.S., Glassberg M.K., Yeung R.S.et al. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J. Biol. Chem. 277(34):2002;30958- 30967.
25. Gao X., Zhang Y., Arrazola P., Hino O., Kobayashi T., Yeung R.S.et al. Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat. Cell Biol. 4(9):2002;699-704.
26. Inoki K., Li Y., Zhu T., Wu J., Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4(9):2002;648-657.
27. Tee A.R., Fingar D.C., Manning B.D., Kwiatkowski D.J., Cantley L.C., Blenis J. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc. Natl. Acad. Sci. USA. 99(21):2002;13571-13576.
28. Onda H., Crino P.B., Zhang H., Murphey R.D., Rastelli L., Gould Rothberg B.E.et al. Tsc2 null murine neuroepithelial cells are a model for human tuber giant cells, and show activation of an mTOR pathway. Mol. Cell Neurosci. 21(4):2002;561-574.
29. Radimerski T., Montagne J., Hemmings-Mieszczak M., Thomas G. Lethality of Drosophila lacking TSC tumor suppressor function rescued by reducing dS6K signaling. Genes Dev. 16(20):2002;2627-2632.
30. Manning B.D., Tee A.R., Logsdon M.N., Blenis J., Cantley L.C. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell. 10(1):2002;151-162.
31. Potter C.J., Pedraza L.O., Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nat. Cell Biol. 4(9):2002;658-665.
32. Dan H.C., Sun M., Yang L., Feldman R.I., Sui X.M., Ou C.C. Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J. Biol. Chem. 277(38):2002;35364-35370.
33. Tee A.R., Anjum R., Blenis J. Inactivation of the tuberous sclerosis complex-1 and -2 gene products occurs by phosphoinositide 3-kinase/ Akt-dependent and -independent phosphorylation of tuberin. J. Biol. Chem. 278(39):2003;37288-37296.
34. Beugnet A., Tee A.R., Taylor P.M., Proud C.O. Regulation of targets of mTOR (mammalian target of rapamycin) signalling by intracellular amino acid availability. Biochem. J. 372(Pt. 2):2003;555-566.
35. Jenne D.E., Reimann H., Nezu J., Friedel W., Loff S., Jeschke R.et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat. Genet. 18(1):1998;38-43.
36. Hemminki A., Markie D., Tomlinson I., Avizienyte E., Roth S., Loukola A.et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature. 391(6663):1998;184-187.
37. Woods A., Johnstone S.R., Dickerson K., Leiper F.C., Fryer L.D., Neumann D.et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr. Biol. 13:2003;2004-2008.
38. Hawley S.A., Boudeau J., Reid J.L., Mustard K.J., Udd L., Makela T.P.et al. Complexes between the LKB1 tumor suppressor, STRADα/β and MO25α/βare upstream kinases in the AMP-activated protein kinase cascade. J. Biol. 2(4):2003;28.1-28.16.
39. Hong S.P., Leiper F.C., Woods A., Carling D., Carlson M. Activation of yeast Snfl and mammalian AMP-activated protein kinase by upstream kinases. Proc. Natl. Acad. Sci. USA. 100(15):2003;8839-8843.
40. Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA, Cantley LC. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA. 2004, In press.
41. Identification and characterization of the tuberous sclerosis gene on chromosome 16. The European Chromosome 16 Tuberous Sclerosis Consortium. Cell 1993;75 (7):1305-15.
42. Tee A.R., Manning B.D., Roux P.P., Cantley L.C., Blenis J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol. 13(15):2003;1259-1268.
43. Zhang Y., Gao X., Saucedo L.J., Ru B., Edgar B.A., Pan D. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat. Cell Biol. 5(6):2003;578-581.
44. Garami A., Zwartkruis F.J., Nobukuni T., Joaquin M., Roccio M., Stocker H.et al. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol. Cell. 11(6):2003;1457-1466.
45. Inoki K., Li Y., Xu T., Guan K.L. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 17(15):2003;1829-1834.
46. Castro A.F., Rebhun J.F., Clark G.J., Quilliam L.A. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. J. Biol. Chem. 278(35):2003;32493-32496.
47. Kim D.H., Sarbassov D.D., Ali S.M., King J.E., Latek R.R., Erdjument-Bromage H.et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell. 110(2):2002;163-175.
48. Hara K., Maruki Y., Long X., Yoshino K., Oshiro N., Hidayat S.et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell. 110(2):2002;177-189.
49. Schalm S.S., Blenis J. Identification of a conserved motif required for mTOR signaling. Curr. Biol. 12(8):2002;632-639.
50. Schalm S.S., Fingar D.C., Sabatini D.M., Blenis J. TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr. Biol. 13(10):2003;797-806.
51. Nojima H., Tokunaga C., Eguchi S., Oshiro N., Hidayat S., Yoshino K.et al. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J. Biol. Chem. 278(18):2003;15461-15464.
52. Kim D.H., Sarbaasov dos D., Ali S.M., Latek R.R., Guntur K.V., Erdjument-Bromage H.et al. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol. Cell. 11(4):2003;895-904.
53. Loewith R., Jacinto E., Wullschleger S., Lorberg A., Crespo J.L., Bonenfant D.et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell. 10(3):2002;457-468.
54. Schmidt A., Kunz J., Hall M.N. TOR2 is required for organization of the actin cytoskeleton in yeast. Proc. Natl. Acad. Sci. USA. 93(24):1996;13780- 13785.
55. Sekulic A., Hudson C.C., Homme J.L., Yin P., Otterness D.M., Karnitz L.M.et al. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res. 60(13):2000;3504-3513.
56. Nave B.T., Ouwens M., Withers D.J., Alessi D.R., Shepherd P.R. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem. J. 344(Pt 2):1999;427-431.
57. Schalm SS, Tee AR, Blenis J. unpublished data.
58. Dennis P.B., Pullen N., Kozma S.C., Thomas G. The principal rapamycin-sensitive p70(s6k) phosphorylation sites, T-229 and T-389, are differentially regulated by rapamycin-insensitive kinase kinases. Mol. Cell Biol. 16(11):1996;6242-6251.
59. Weng Q.P., Andrabi K., Kozlowski M.T., Grove J.R., Avruch J. Multiple independent inputs are required for activation of the p70 S6 kinase. Mol. Cell Biol. 15(5):1995;2333-2340.
60. Cheatham L., Moufar M., Chou M.M., Blenis J. Structural and functional analysis of pp70 S6 kinase. Proc. Natl. Acad. Sci. USA. 92(25):1995;11696-11700.
61. Romanelli A., Dreisbach V.C., Blenis J. Characterization of phosphatidylinositol 3-kinase-dependent phosphorylation of the hydrophobic motif site Thr(389) in p70 S6 kinase 1. J. Biol. Chem. 277(43):2002;40281-40289.
62. Pullen N., Dennis P.B., Andjelkovic M., Dufner A., Kozma S.C., Hemmings B.A.et al. Phosphorylation and activation of p70s6k by PDK1. Science. 279(5351):1998;707-710.
63. Alessi D.R., Kozlowski M.T., Weng Q.P., Morrice N., Avruch J. 3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro. Curr. Biol. 8(2):1998;69-81.
64. Williams M.R., Arthur J.S., Balendran A., van der Kaay J., Poli V., Cohen P.et al. The role of 3-phosphoinositide-dependent protein kinase 1 in activating AGC kinases defined in embryonic stem cells. Curr. Biol. 10(8):2000;439-448.
65. Romanelli A., Martin K.A., Toker A., Blenis J. p70 S6 kinase is regulated by protein kinase Czeta and participates in a phosphoinositide 3-kinase-regulated signalling complex. Mol. Cell Biol. 19(4):1999;2921-2928.
66. Akimoto K., Nakaya M., Yamanaka T., Tanaka J., Matsuda S., Weng Q.P.et al. Atypical protein kinase Clambda binds and regulates p70 S6 kinase. Biochem. J. 335(Pt. 2):1998;417-424.
67. Coghlan M.P., Chou M.M., Carpenter C.L. Atypical protein kinases Clambda and -zeta associate with the GTP-binding protein Cdc42 and mediate stress fiber loss. Mol. Cell Biol. 20(8):2000;2880-2889.
68. Martin K.A., Schalm S.S., Richardson C., Romanelli A., Keon K.L., Blenis J. Regulation of ribosomal S6 kinase 2 by effectors of the phosphoinositide 3-kinase pathway. J. Biol. Chem. 276(11):2001;7884-7891.
69. Martin K.A., Schalm S.S., Romanelli A., Keon K.L., Blenis J. Ribosomal S6 kinase 2 inhibition by a potent C-terminal repressor domain is relieved by mitogen-activated protein-extracellular signal- regulated kinase kinase-regulated phosphorylation. J. Biol. Chem. 276(11):2001;7892-7898.
70. Dufner A., Andjelkovic M., Burgering B.M., Hemmings B.A., Thomas G. Protein kinase B localization and activation differentially affect S6 kinase 1 activity and eukaryotic translation initiation factor 4E-binding protein 1 phosphorylation. Mol. Cell Biol. 19(6):1999;4525-4534.
71. Peng X.D., Xu P.Z., Chen M.L., Hahn-Windgassen A., Skeen J., Jacobs J.et al. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dcv. 17(11):2003;1352-1365.
72. Chen C., Jack J., Garofalo R.S. The Drosophila insulin receptor is required for normal growth. Endocrinology. 137(3):1996;846-856.
73. Bohni R., Riesgo-Escovar J., Oldham S., Brogiolo W., Stocker H., Andruss B.F.et al. Autonomous control of cell and organ size by CHICO, a Drosophila homolog of vertebrate IRS1-4. Cell. 97(7):1999;865-875.
74. Weinkove D., Neufeld T.P., Twardzik T., Waterfield M.D., Leevers S.J. Regulation of imaginal disc cell size, cell number and organ size by Drosophila class I(A) phosphoinositide 3-kinase and its adaptor. Curr. Biol. 9(18):1999;1019-1029.
75. Rintelen F., Stocker H., Thomas G., Hafen E. PDK1 regulates growth through Akt and S6K in Drosophila. Proc. Natl. Acad. Sci. USA. 98(26):2001;15020-15025.
76. Saucedo U., Gao X., Chiarelli D.A., Li L., Pan D., Edgar B.A. Rheb promotes cell growth as a component of the insulin/TOR signalling network. Nat. Cell Biol. 5(6):2003;566-571.
77. Patel P.H., Thapar N., Guo L., Martinez M., Maris J., Gau C.L.et al. Drosophila Rheb GTPase is required for cell cycle progression and cell growth. J. Cell Sci. 116(Pt 17):2003;3601-3610.
78. Stocker H., Radimerski T., Schindelholz B., Wittwer F., Belawat P., Dararn P.et al. Rheb is an essential regulator of S6K in controlling cell growth in Drosophila. Nat. Cell Biol. 5(6):2003;559-565.
79. Gao X., Pan D. TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev. 15(11):2001;1383-1392.
80. Tapon N., Ito N., Dickson B.J., Treisman J.E., Hariharan I.K. The Drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation. Cell. 105(3):2001;345-355.
81. Potter C.J., Huang H., Xu T. Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell. 105(3):2001;357-368.
82. Goberdhan D.C., Paricio N., Goodman E.C., Mlodzik M., Wilson C. Drosophila tumor suppressor PTEN controls cell size and number by antagonizing the Chico/PI3-kinase signaling pathway. Genes Dev. 13(24):1999;3244-3258.
83. Miron M., Verdu J., Lachance P.E., Birnbaum M.J., Lasko P.F., Sonenberg N. The translational inhibitor 4E-BP is an effector of PI(3)K/Akt signalling and cell growth in Drosophila. Nat. Cell Biol. 3(6):2001;596-601.
84. Montagne J., Stewart M.J., Stocker H., Hafen B., Kozma S.C., Thomas G. Drosophila S6 kinase: a regulator of cell size. Science. 285(5436):1999;2126- 2129.
85. Verdu J., Buratovich M.A., Wilder E.L., Birnbaum M.J. Cell-autonomous regulation of cell and organ growth in Drosophila by Akt/PKB. Nat. Cell Biol. 1(8):1999;500-506.
86. Lizcano J.M., Alrubaie S., Kieloch A., Deak M., Leevers S.J., Alessi D.R. Insulin-induced Drosophila S6 kinase activation requires phosphoinositide 3-kinase and protein kinase B. Biochem. J. 374(Pt 2):2003;297-306.
87. Miron M., Lasko P., Sonenberg N. Signaling from Akt to FRAP/TOR targets both 4E-BP and S6K in Drosophila melanogaster. Mol. Cell Biol. 23(24):2003;9117-9126.
88. Colombani J., Raisin S., Pantalacci S., Radimerski T., Montagne J., Leopold P. A nutrient sensor mechanism controls Drosophila growth. Cell. 114:2003;739-749.
89. Cantley L.C., Neel B.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. USA. 96(8):1999;4240-4245.
90. Aoki M., Blazek E., Vogt P.K. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc. Natl. Acad. Sci. USA. 98(1):2001;136-141.
91. Podsypanina K., Lee R.T., Politis C., Hennessy I., Crane A., Puc J.et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten± mice. Proc. Natl. Acad. Sci. USA. 98(18):2001;10320-10325.
92. Neshat M.S., Mellinghoff I.K., Tran C., Stiles B., Thomas O., Petersen R.et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA. 98(18):2001;10314-10319.
93. Mills G.B., Lu Y., Kohn E.C. Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc. Natl. Acad. Sci. USA. 98(18):2001;10031-10033.
94. Kwiatkowski D.J. Tuberous sclerosis: from tubers to mTOR. Ann. Hum. Genet. 67(Pt 1):2003;87-96.
95. Kwiatkowski D.J., Zhang H., Bandura J.L., Heiberger K.M., Glogauer M., el-Hashemite N.et al. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70 S6 kinase activity in Tsc1 null cells. Hum. Mol. Genet. 11(5):2002;525-534.
96. Lazaris-Karatzas A., Montine K.S., Sonenberg N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap. Nature. 345(6275):1990;544-547.
97. Fingar D.C., Salama S., Tsou C., Harlow E., Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 16(12):2002;1472-1487.
98. Shima H., Pende M., Chen Y., Fumagalli S., Thomas G., Kozma S.C. Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J. 17(22):1998;6649-6659.
99. Alvarez B., Garrido E., Garcia-Sanz J.A., Carrera A.C. Phosphoinositide 3-kinase activation regulates cell division time by coordinated control of cell mass and cell cycle progression rate. J. Biol. Chem. 278(29):2003;26466-26473.
100. Faridi J., Fawcett J., Wang L., Roth R.A. Akt promotes increased mammalian cell size by stimulating protein synthesis and inhibiting protein degradation. Am. J. Physiol. Endocrinol. Metab. 285(5):2003;E964-E972.
101. Rommel C., Bodine S.C., Clarke B.A., Rossman R., Nunez L., Stitt T.N.et al. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat. Cell Biol. 3(11):2001;1009-1013.
102. Johnston G.C., Pringle J.R., Hartwell L.H. Coordination of growth with cell division in the yeast Saccharomyces cerevisiae. Exp. Cell Res. 105(1):1977;79-98.
103. Neufeld T.P., de la Cruz A.F., Johnston L.A., Edgar B.A. Coordination of growth and cell division in the Drosophila wing. Cell. 93(7):1998;1183-1193.
104. Fingar DC, Richardson C, Tee AR, Cheatham L, Tsou C, Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4B-BP1/eIF4E. Mol Cell Biol 2004;24(1):200-216.
105. Datar S.A., Jacobs H.W., de la Cruz A.F., Lehner C.F., Edgar B.A. The Drosophila cyclin D-Cdk4 complex promotes cellular growth. EMBO J. 19(17):2000;4543-4554.
106. Terada N., Patel H.R., Takase K., Kohno K., Nairn A.C., Gelfand E.W. Rapamycin selectively inhibits translation of mRNAs encoding elongation factors and ribosomal proteins. Proc. Natl. Acad. Sci. USA. 91(24):1994;11477-11481.
107. Jefferies H.B., Reinhard C., Kozma S.C., Thomas G. Rapamycin selectively represses translation of the "polypyrimidine tract" mRNA family. Proc. Natl. Acad. Sci. USA. 91(10):1994;4441-4445.
108. Pedersen S., Celis J.E., Nielsen J., Christiansen J., Nielsen F.C. Distinct repression of translation by wortmannin and rapamycin. Eur. J. Biochem. 247(1):1997;449-456.
109. Kawasome H., Papst P., Webb S., Keller G.M., Johnson G.L., Gelfand E.W. et al. Targeted disruption of p70(s6k) defines its role in protein synthesis and rapamycin sensitivity. Proc. Natl. Acad. Sci. USA. 95(9):1998;5033-5038.
110. Rajasekhar V.K., Viale A., Socci N.D., Wiedmann M., Hu X., Holland E.C. Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol. Cell. 12(4):2003;889-901.
111. Gingras A.C., Raught B., Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu. Rev. Biochem. 68:1999;913-963.
112. Sonenberg N., Gingras A.C. The mRNA 5′ cap-binding protein eIF4E and control of cell growth. Curr. Opin. Cell Biol. 10(2):1998;268-275.
113. Marcotrigiano J., Gingras A.C., Sonenberg N., Burley S.K. Cap-dependent translation initiation in eukaryotes is regulated by a molecular mimic of eIF4G. Mol. Cell. 3(6):1999;707-716.
114. Rau M., Ohlmann T., Morley S.J., Pain V.M. A reevaluation of the cap-binding protein, eIF4E, as a rate-limiting factor for initiation of translation in reticulocyte lysate. J. Biol. Chem. 271(15):1996;8983-8990.
115. Kozak M. Structural features in eukaryotic mRNAs that modulate the initiation of translation. J. Biol. Chem. 266(30):1991;19867-19870.
116. Jefferies H.B., Fumagalli S., Dennis P.B., Reinhard C., Pearson R.B., Thomas G. Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k. EMBO J. 16(12):1997;3693-3704.
117. Hornstein E., Git A., Braunstein I., Avni D., Meyuhas O. The expression of poly(A) binding protein gene is translationally regulated in a growth-dependent fashion through a 5′-terminal oligopyrimidine tract motif. J. Biol. Chem. 274(3):1999;1708-1714.
118. Tang H., Hornstein E., Stolovich M., Levy G., Livingstone M., Templeton D.et al. Amino acid-induced translation of TOP mRNAs is fully dependent on phosphatidylinositol 3-kinase-mediated signaling, is partially inhibited by rapamycin, and is independent of S6K1 and rpS6 phosphorylation. Mol. Cell Biol. 21(24):2001;8671-8683.
119. Stolovich M., Tang H., Hornstein E., Levy G., Cohen R., Bac S.S.et al. Transduction of growth or mitogenic signals into translational activation of TOP mRNAs is fully reliant on the phosphatidylinositol 3- kinase-mediated pathway but requires neither S6K1 nor rpS6 phosphorylation. Mol. Cell Biol. 22(23):2002;8101-8113.
120. Barth-Baus D., Stratton C.A., Parrott L., Myerson H., Meyuhas O., Templeton D.J.et al. S6 phosphorylation-independent pathways regulate translation of 5′-terminal oligopyrimidine tract-containing mRNAs in differentiating hematopoietic cells. Nucleic Acids Res. 30(9):2002;1919-1928.
121. Wang X., Li W., Williams M., Terada N., Alessi D.R., Proud C.G. Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase. EMBO J. 20(16):2001;4370-4379.
122. Cardenas M.E., Cutler N.S., Lorenz M.C., Di Como C.J., Heitman J. The TOR signaling cascade regulates gene expression in response to nutrients. Genes Dev. 13(24):1999;3271-3279.
123. Hardwick J.S., Kuruvilla F.G., Tong J.K., Shamji A.F., Schreiber S.L. Rapamycin-modulated transcription defines the subset of nutrient-sensitive signaling pathways directly controlled by the Tor proteins. Proc. Natl. Acad. Sci. USA. 96(26):1999;14866-14870.
124. Beck T., Hall M.N. The TOR signalling pathway controls nuclear localization of nutrient-regulated transcription factors. Nature. 402(6762):1999;689-692.
125. Shamji A.F., Kuruvilla F.G., Schreiber S.L. Partitioning the transcriptional program induced by rapamycin among the effectors of the Tor proteins. Curr. Biol. 10(24):2000;1574-1581.
126. Powers T., Walter P. Regulation of ribosome biogenesis by the rapamycin-sensitive TOR-signaling pathway in Saccharomyces cerevisae. Mol. Biol. Cell. 10(4):1999;987-1000.
127. Beck T., Schmidt A., Hall M.N. Starvation induces vacuolar targeting and degradation of the tryptophan permease in yeast. J. Cell Biol. 146(6):1999;1227-1238.
128. Schmidt A., Beck T., Koller A., Kunz J., Hall M.N. The TOR nutrient signalling pathway phosphorylates NPR1 and inhibits turnover of the tryptophan permease. EMBO J. 17(23):1998;6924-6931.
129. Noda T., Ohsumi Y. Tor, a phosphatidylinositol kinase homologue, controls autophagy in yeast. J. Biol. Chem. 273(7):1999;3963-3966.
130. Peng T., Golub T.R., Sabatini D.M. The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol. Cell Biol. 22(15):2002;5575-5584.
131. de Groot R.P., Ballou L.M., Sassone-Corsi P. Positive regulation of the cAMP-responsive activator CREM by the p70 S6 kinase: an alternative route to mitogen-induced gene expression. Cell. 79(1):1994;81-91.
132. Hudson C.C., Liu M., Chiang G.G., Otterness D.M., Loomis D.C., Kaper F. et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol. Cell Biol. 22(20):2002;7004-7014.
133. Gstager M., Luke B., Hess D., Oakeley E.J., Wirbelanuer C., Blondel M.et al. Control of nutrient-sensitive transcription programs by the unconventional prefoldin URI. Science. 302(5648):2003;1208-1212.
134. Hannan K.M., Brandenburger Y., Jenkins A., Sharkey K., Cavanaugh A., Rothblum L.et al. mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF. Mol. Cell Biol. 23(23):2003;8862-8877.
135. Tsang C.K., Bertram P.G., Ai W., Drenan R., Zheng X.F. Chromatin-mediated regulation of nucleolar structure and RNA Pol I localization by TOR. EMBO J. 22(22):2003;6045-6056.
136. Wilson K.F., Wu W.J., Cerione R.A. Cdc42 stimulates RNA splicing via the S6 kinase and a novel S6 kinase target, the nuclear cap-binding complex. J. Biol. Chem. 275(48):2000;37307-37310.
137. Richardson C, Blenis J. Unpublished data.
138. Maniatis T., Reed R. An extensive network of coupling among gene expression machines. Nature. 416(6880):2002;499-506.
139. Blommaart E.F., Luiken J.J., Blommaart P.J., van Woerkom G.M., Meijer A.J. Phosphorylation of ribosomal protein S6 is inhibitory for autophagy in isolated rat hepatocytes. J. Biol. Chem. 270(5):1995;2320-2326.
140. Shigemitsu K., Tsujishita Y., Miyake H., Hidayat S., Tanaka N., Hara K. et al. Structural requirement of leucine for activation of p70 S6 kinase. FEBS Lett. 447(2/3):1999;303-306.
141. Helliwell P.A., Rumaby M.G., Kellett G.L. Intestinal sugar absorption is regulated by phosphorylation and turnover of protein kinase C betaII mediated by phosphatidylinositol 3-kinase- and mammalian target of rapamycin-dependent pathways. J. Biol. Chem. 278(31):2003;28644-28650.
142. Harada H., Andersen J.S., Mann M., Terada N., Korsmeyer S.J. p70 S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc. Natl. Acad. Sci. USA. 98(17):2001;9666-9670.
143. Edinger A.L., Thompson C.B. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol. Biol. Cell. 13(7):2002;2276- 2288.
144. Sehgal S.N. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc. 35(Suppl. 3):2003;S7-S14.
145. Morice M.C., Serruys P.W., Sousa J.E., Fajadet J., Ban Hayashi E., Perin M.et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. 346(23):2002;1773-1780.
146. Sousa J.E., Costa M.A., Abizaid A.C., Rensing B.J., Abizaid A.S., Tanajura L.F.et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation. 104(17):2001;2007-2011.